Differences of Interleukin-6 Serum Levels in Lung Cancer Patients and Healthy Individuals in Medan

Dumasari Siagian, Noni Novisari Soeroso, Bintang Yinke Magdalena Sinaga, Putri C Eyanoer

Abstract


Background: Interleukin-6 (IL-6) is a pro-inflammatory cytokines involved in the development of lung cancer. However, the association of IL-6 in lung cancer patients remains uncertain. The aim of this study was to analyze the difference of IL-6 serum levels in lung cancer patients and healthy individuals in Medan. Methods: This was a case-control study that included 42 lung cancer patients (case) and 42 healthy individuals (control) which was held in Haji Adam Malik General Hospital Medan. The examinations of IL-6 serum levels were conducted for all subjects using ELISA method. Differences of IL-6 serum levels in lung cancer patients and healthy individuals were analyzed using Spearman Correlation test. Results: The mean serum IL-6 levels in lung cancer patients was 45.99 pg/ml while in healthy individuals was 6.24 pg/ml. There was a significant difference of serum IL-6 levels in the lung cancer group compared to healthy individuals (P=0.0005;r=0.854). Conclusion: There was a statistically significant difference of IL-6 serum levels between lung cancer patients and healthy individuals.

Keywords


Proinflammatory Cytokine; IL-6; Lung Cancer

References


Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2006; 56:106–30.

Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S. Kanker Paru (Kanker Paru Jenis Karsinoma Bukan Sel Kecil): Pedoman Diagnosis & Penatalaksanaan di Indonesia. Jakarta: PDPI; 2016. p3.

Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer. Cochrane Database Syst Rev. 2004;1:CD001991.

Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010;29(2):273–83.

Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, et al. A cytokine gene signature of the lung adenocarcinoma and its tissue environment predicts prognosis. J Natl Cancer Inst. 2007;99(16):1257–69.

Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98(17):9824–29.

Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology. 2006;70(2):115–25.

Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995;71(5):1095–8.

Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circu¬lating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22(10):1668–73.

Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2002;39(3):149–54.

Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, et al. Increased expression of inflam¬matory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol. 2000;278(5):L906–13.

Tarrant JM. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci.2010.117:4–16.

Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, et al. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol.2014. 33:383–401.

Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, et al. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology. 2016;5:e1115942.

Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4:221-33.

Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S. Kanker Paru (Kanker Paru Jenis Karsinoma Bukan Sel Kecil): Pedoman Diagnosis & Penatalaksanaan di Indonesia. Jakarta: PDPI. 2018. p7.

Ridge C, McErlean A, Ginsberg M. Epidemiology of Lung Cancer. Semin Intervent Radiol. 2013;30(2):93-8.

Margono BP. Kanker Paru. In Wibisono MJ, Winariani, Hariadi S ed. Buku Ajar Ilmu Penyakit Paru 2010. Surabaya: Departemen Ilmu Penyakit Paru UNAIR-RSUD Dr. Soetomo. 2010. p.88-110.

Furrukh M. Tobacco Smoking and Lung Cancer. Sultan Qaboos Univ Med J. 2013;13(3):345-58.




DOI: https://doi.org/10.36497/jri.v41i1.155

Refbacks

  • There are currently no refbacks.




Copyright (c) 2021 Dumasari Siagian, Noni Novisari Soeroso, Bintang Yinke Magdalena Sinaga, Putri C Eyanoer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


INDEXING & PARTNER

SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 

 

Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845
Email: editor@jurnalrespirologi.org


An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License

Statcounter